GlassScriptPhysician profile
Fernando Cabanillas
NPI 1811052707
$26,420.76
in general payments reported to CMS, 2019-2025
42 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,860 · 2021: $2,933 · 2022: $915 · 2023: $1,177 · 2024: $1,373 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.77 |
| Education | $178.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $9,419.89 | 2019-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $4,060.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $3,279.36 | 2019-2024 | Darzalex, Rybrevant, Erleada |
| E.R. Squibb & Sons, L.L.C. | $2,825.26 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Abbvie INC. | $1,908.40 | 2020-2025 | Epkinly, Venclexta |
| Novartis Pharmaceuticals Corporation | $956.39 | 2019-2025 | |
| Pbg Puerto Rico LLC | $573.00 | 2019-2025 | |
| Genentech USA, INC. | $425.59 | 2019-2024 | Lunsumio, Polivy, Columvi |
| Eli Lilly Export S.A. Puerto Rico Branch | $380.14 | 2019-2023 | Jaypirca |
| Tempus Ai, INC | $278.90 | 2024-2025 | Xt Cdx |
| Taiho Oncology, INC. | $210.27 | 2019-2025 | |
| Adc Therapeutics America, INC. | $209.48 | 2021-2024 | |
| Astellas Pharma US INC | $198.64 | 2020-2025 | Xospata, Padcev |
| Incyte Corporation | $195.28 | 2021-2024 | Monjuvi, Pemazyre |
| Stemline Therapeutics INC. | $163.57 | 2021 |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Cabanillas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.